Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies

Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK